SkinDuoTM as a Targeted Probiotic Therapy: Shifts in Skin Microbiota and Clinical Outcomes in Acne Patients
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115000 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Manuele Biazzo und 2 weiteren Autor:innen. Beteiligte Einrichtung: The BioArte Ltd., Malta Life Science Park (LS2.1.10, LS2.1.12-LS2.1.15), Triq San Giljan, SGN 3000 San Gwann, Malta. Hauptthemen laut MEDLINE: Probiotics, Acne Vulgaris, Skin, Microbiota. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xjenza Malta, Xjenza Malta (Villa Bighi, Kalkara KKR 1320, Malta) through the FUSION: R&I Technology Development Program LITE.
Abstract (Originalsprache)
Acne vulgaris is a common dermatological condition strongly associated with disruptions in the skin microbiota, specifically involving key species such as Cutibacterium acnes and Staphylococcus epidermidis. This study investigates the efficacy of SkinDuoTM, a topical probiotic containing Lactiplantibacillus plantarum, in modulating the skin microbiota and improving clinical outcomes in patients with acne vulgaris. Over a 4-week to 8-week observational study period, microbial composition and diversity shifts were analyzed using full-length 16S rRNA sequencing. Patient responses were categorized into “good” responders (showing significant clinical improvement) and “no_change” responders (with minimal or no improvement). SkinDuoTM treatment resulted in lower post-treatment Cutibacterium acnes abundance in the “good” group compared to the “no_change” group. The “good” group maintained a stable level of alpha diversity following treatment. In contrast, the “no_change” group exhibited a marked reduction in microbial diversity. Beta diversity analysis revealed distinct clustering patterns associated with improved clinical outcomes. These findings suggest that the preservation of microbial richness and evenness may serve as a potential biomarker for positive response to probiotic therapy. This study highlights the potential of SkinDuoTM to restore microbial balance and alleviate acne symptoms, contributing to the growing body of evidence supporting microbiome-based therapeutic strategies in dermatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The BioArte Ltd., Malta Life Science Park (LS2.1.10, LS2.1.12-LS2.1.15), Triq San Giljan, SGN 3000 San Gwann, Malta.
ORCID-Profile: Manuele Biazzo, David Pinzauti, Christine Podrini
Förderung
- Xjenza Malta
- Xjenza Malta (Villa Bighi, Kalkara KKR 1320, Malta) through the FUSION: R&I Technology Development Program LITE
Zitieren
APA
Biazzo, M., Pinzauti, D., & Podrini, C. (2025). SkinDuoTM as a Targeted Probiotic Therapy: Shifts in Skin Microbiota and Clinical Outcomes in Acne Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115000
Vancouver
Biazzo M, Pinzauti D, Podrini C. SkinDuoTM as a Targeted Probiotic Therapy: Shifts in Skin Microbiota and Clinical Outcomes in Acne Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115000
BibTeX
@article{Biazzo2025,
author = {Biazzo, Manuele and Pinzauti, David and Podrini, Christine},
title = {SkinDuoTM as a Targeted Probiotic Therapy: Shifts in Skin Microbiota and Clinical Outcomes in Acne Patients},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115000}
}
EUVIMED